Articles related to GUIDELINES/RECOMMENDATIONS

An update from the original ASCO guideline on this topic published in 2012, 60 studies, primarily retrospective, were included in the review. New to this version of the guideline, the Panel offers recommendations on approved doses of immunotherapy and targeted therapies that can be offered to obese patients with cancer.

Since April 2021, there have been reports of myocarditis and/or pericarditis after receipt of an m-RNA COVID-19 vaccine, according to the Centers for Disease Control and Prevention (CDC) . Most cases have been among male adolescents and young adults ages 16 and older, typically occurring within several days after the second dose of m-RNA COVID-19 vaccine.

These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the prevention and treatment of venous thromboembolism (VTE)  – a common complication among patients with cancer who are at a markedly increased risk for morbidity and mortality.

These evidence-based guidelines from the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) are intended to support patients, clinicians, and health care professionals in their decisions about management of von Willebrand Disease (VWD), a common inherited bleeding disorder.

The American Society of Clinical Oncology (ASCO) published a guideline update about the selection of optimal adjuvant chemotherapy regimens and targeted therapy for early breast cancer, namely trastuzumab emtansine. In a second recommendation, the ASCO guideline addressed the use of biosimilar forms of trastuzumab—five of which have been approved by the FDA.

The American Society of Hematology (ASH) used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess evidence and make recommendations toward the treatment of venous thromboembolism (VTE). The panel agreed on 28 recommendations for the initial management of VTE, primary treatment, secondary prevention, and treatment of recurrent VTE events.